Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied

Novo Nordisk is grappling with intense competition for its Wegovy obesity drug, primarily from lower-priced compounded versions and Eli Lilly, which led to a $95 billion market value loss last week and a lowered sales outlook. Despite an FDA ban, over one million U.S. patients still use compounded GLP-1s, prompting Novo to pursue legal action and expand its direct-to-consumer platform while anticipating deeper U.S. pricing erosion in H2. To mitigate these pressures and maintain profitability, the company is implementing cost efficiencies, including terminating eight R&D projects, as its shares continue to face investor scrutiny.

Analysis

Novo Nordisk is confronting a significant erosion of investor confidence following a profit warning and a 30% weekly stock decline, its worst in over two decades, which erased $95 billion in market value. The core issue is unexpectedly persistent competition from compounded copycat versions of its Wegovy obesity drug, which the company now projects will not decline this year, a sharp reversal from its previous guidance. This compounded market, utilized by over one million U.S. patients, is described by the outgoing CEO as having an "equal size to our business" at a much lower price point, directly challenging Wegovy's market position alongside rival Eli Lilly's Zepbound. While second-quarter sales grew 18% to 76.86 billion DKK, this figure missed initial analyst expectations. Furthermore, Barclays analysts anticipate deeper U.S. pricing erosion in the second half due to higher rebates and a strategic shift toward direct-to-consumer channels. In response, Novo is pursuing legal action against compounding pharmacies, expanding its NovoCare direct sales platform, and implementing cost-saving measures, including the termination of eight R&D projects, a move Jefferies analysts noted as a potentially strategic re-assessment.

Key Decisions for Investors

• Investors should recognize that Novo Nordisk's revised, weaker outlook and the acknowledgment of persistent competition from compounded drugs introduce significant uncertainty, justifying the recent cuts to analyst price targets and recommendations.
• The ongoing legal battles against compounding pharmacies and the performance of the direct-to-consumer sales channel are now critical catalysts to monitor, as they will directly impact the company's ability to defend its U.S. market share and pricing power.
• The operational headwinds facing Novo Nordisk present a clear competitive advantage for Eli Lilly, whose Zepbound drug is positioned to capture further market share, making the relative performance of NVO and LLY a key pair trade consideration.
• The termination of eight R&D projects as a cost-cutting measure warrants scrutiny, as it may signal pressure on profitability that could impact the company's long-term innovation pipeline and competitive standing.